Aleksandra Piech

Aleksandra Piech

Auto-generated profile, based on publicly available information

Aleksandra Piech

Clinical Provincial Hospital No. 2 in Rzeszów, Rzeszów, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
PUPatrycja Ucieklak
Patrycja Ucieklak
MUMonika Ucieklak
Monika Ucieklak
JUJarosław Ucieklak
Jarosław Ucieklak
DMDawid Musialik
Dawid Musialik
KPKarol Poplicha
Karol Poplicha
KPKarolina Pasierb
Karolina Pasierb
Background: Pacifier use remains a common practice during infancy and early childhood worldwide that has both benefits and risks. Its use has become highly prevalent in recent years and is sometimes considered overused, as it provides an easy and convenient method for calming and soothing children. Objective: This review aims to summarize current scientific evidence regarding pacifier use focusing on both positive and negative outcomes to provide an overview that may help with the establishment of the clinical recommendations. Methods: A narrative review of different randomized controlled trials and cohort studies investigating the positive and negative impacts of pacifier use such as SIDS risk, pain management, otitis media, dental malocclusions and breast-feeding. Results: The reviewed studies indicate that pacifier use reduces risk of sudden infant death syndrome (SIDS) and is an effective way of pain management during minor medical procedures. However, evidence shows an association between pacifier use and increased incidence of acute otitis media, dental malocclusions in cases of prolonged use and negative impact on breastfeeding when introduced before lactation is well established. Conclusion: The evidence supports selective use of pacifier, particularly during the first year of life with its introduction delayed until breastfeeding is well established, which happens usually around 1 month of age. Its use should be limited mainly to sleep periods and gradually limited by 12 months of age. Proper timing and restricted duration are key to maximising benefits while reducing risks.

16 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
APAleksandra Piech
Aleksandra Piech
KPKarolina Pasierb
Karolina Pasierb
TUTomasz Andrzej Ufniarski
Tomasz Andrzej Ufniarski
MGMartyna Grodzińska
Martyna Grodzińska
MUMaria Ufniarska
Maria Ufniarska
PUPatrycja Ucieklak
Patrycja Ucieklak
Venous thromboembolism (VTE), which consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), is one of the most common cardiovascular diseases. Despite improvements in prevention, diagnosis, and treatment, its mortality rates are still high and remain a major problem in public health. The World Health Organization (WHO) recommends that adults (aged 18–64 years) engage in at least 150–300 minutes of moderate-intensity aerobic physical activity or 75–150 minutes of vigorous-intensity aerobic activity per week. Prolonged sedentary behavior contributes to increased venous compression in the lower extremities, leading to reduced venous return and an elevated risk of VTE. Many studies have observed a risk increase of up to 2-10% per additional hour of prolonged sitting. In the literature, a positive correlation was found between higher levels of PA and reduced risk of VTE, indicating a significant reduction in risk for those with higher levels of PA, even at levels below norms established by the WHO. However, some research indicates that the highest level of physical exertion—defined as regularly engaging in hard physical training (i.e., vigorous exercise or participation in competitive sports several times per week)—was associated with a twofold increased risk of first-time VTE. The aim of this review is to provide a general overview of the impact of physical activity on venous thromboembolism. Material and method: A review of available literature from the PubMed database from 2005 to 2024.

24 March 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
BSBartłomiej Siuzdak
Bartłomiej Siuzdak
APAleksandra Piech
Aleksandra Piech
WMWiktoria Mika
Wiktoria Mika
KPKarolina Pasierb
Karolina Pasierb
TUTomasz Andrzej Ufniarski
Tomasz Andrzej Ufniarski
MJMarta Jutrzenka
Marta Jutrzenka
Chronic wounds are a significant clinical and socioeconomic burden, causing major health concerns and associated costs in terms of quality of life. Conventional solutions like debridement, gauze dressings, systemic antibiotics and offloading continue to be widely used due to their accessibility and low cost, although they may not be adequate for advanced or long-standing cases. This manuscript reviews and contrasts traditional and novel management techniques in chronic wound care. Advanced dressings providing a moist environment, negative pressure wound therapy (NPWT) and bioengineered matrices provide better healing, reduced infection risk, and lower long-term costs than other conventional approaches. Smart dressings incorporating biosensors and emerging therapies, such as nanomedicine, stem cells and growth factors, also have great promise, but require large-scale validation. Conventional strategies continue to be useful in initial and less complicated wounds but modern, individualized, and multi-disciplinary care is becoming more important in achieving better outcomes. Integrating both approaches, following EWMA and NICE guidelines, appears most effective to deliver on innovation, accessibility and cost-effectiveness in chronic wound care. Material and method: This study employed a narrative review approach based on the analysis of recent scientific publications, international guidelines (EWMA, NICE), and clinical trial results comparing traditional and modern strategies for the management of chronic wounds.

11 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KPKarol Poplicha
Karol Poplicha
PSPiotr Sobkiewicz
Piotr Sobkiewicz
APAleksandra Piech
Aleksandra Piech
KPKonrad Poplicha
Konrad Poplicha
PUPatrycja Ucieklak
Patrycja Ucieklak
JUJarosław Ucieklak
Jarosław Ucieklak
Background: There is growing evidence to support an association between the SARS-CoV-2 infection and the onset or flare of ADs (autoimmune diseases) in pediatric and adult patients. Immunological factors in these processes include molecular mimicry, hyperactivation of the immune system, and others. Moreover, a new clinical entity (Multisystem Inflammatory Syndrome in Children (MIS-C)) is an example of a severe immunologic mediated pattern after COVID-19. Objective: This review describes available evidence regarding the impact of COVID-19 infection on the occurrence and course of autoimmune diseases in children as well as in adults. Significant emphasis is placed on population studies regarding the diagnosis of autoimmune diseases and their natural history, the immunological mechanisms, and the impact of COVID-19 vaccination in the setting of autoimmunity. Methods: This review was conducted using findings of scientific search databases PubMed, Google Scholar and Scopus with words: COVID-19, SARS-CoV-2, autoimmunity, autoimmune diseases, rheumatic diseases, COVID-19 vaccination, MIS-C, molecular mimicry. Articles were selected based on relevance, methodological quality, and adherence to PRISMA 2020 guidelines. Results: The immune dysregulation of SARS-CoV-2 infection might induce the onset of autoimmune diseases. Increased rates of newly diagnosed autoimmune diseases, such as type 1 diabetes, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA), have been reported in both adult and pediatric populations following COVID-19. While autoimmune phenomena may rarely occur with COVID-19 vaccines, the risk is much higher with natural infection. Conclusion: Further studies and systematic immunological follow-up of patients after COVID-19 are essential for the early detection and effective management of autoimmune complication.

11 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MUMaria Ufniarska
Maria Ufniarska
TUTomasz Andrzej Ufniarski
Tomasz Andrzej Ufniarski
APAleksandra Piech
Aleksandra Piech
KPKarolina Pasierb
Karolina Pasierb
KPKarol Poplicha
Karol Poplicha
PUPatrycja Ucieklak
Patrycja Ucieklak
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques, tau neurofibrillary tangles, and other pathological factors like neuroinflammation and oxidative stress. This review discusses the effectiveness of Lanacemab and Donanemab - new anti-amyloid monoclonal antibodies- for the treatment of early Alzheimer’s Disease. While no cure exists, current symptomatic treatments are complemented by emerging disease-modifying therapies (DMTs). Recent breakthroughs with anti-amyloid monoclonal antibodies, Lecanemab and Donanemab, show promise in slowing disease progression. Clinical trials like CLARITY-AD for Lecanemab and TRAILBLAZER-ALZ 2 for Donanemab demonstrated significant reductions in brain amyloid and a slowed cognitive and functional decline in early AD. Lecanemab selectively targets Aβ protofibrils, while Donanemab targets N-terminally truncated Aβ in plaques, both facilitating amyloid clearance. These DMTs, though associated with side effects like ARIA, mark a pivotal shift towards targeting underlying AD pathology, offering hope for more effective interventions and potentially preventive strategies, such as those explored in the TRAILBLAZER-ALZ 3 trial.

12 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MJMarta Jutrzenka
Marta Jutrzenka
JMJustyna Moszkowicz
Justyna Moszkowicz
TUTomasz Andrzej Ufniarski
Tomasz Andrzej Ufniarski
APAleksandra Piech
Aleksandra Piech
MKMaria Kleczkowska
Maria Kleczkowska
PUPatrycja Ucieklak
Patrycja Ucieklak
Diabetes mellitus (DM) is a progressive metabolic disorder with increasing global prevalence and a wide variety of complications. While clinical attention focuses mostly on its vascular pathologies, musculoskeletal disorders remain under-recognized and poorly managed. This review provides an overview of musculoskeletal complications associated with both type 1 and 2 diabetes, including bone fragility, Charcot neuroarthropathy, diffuse idiopathic skeletal hyperostosis, osteoarthritis, adhesive capsulitis, diabetic amyotrophy, and diabetic muscle infarction. The pathophysiology of these conditions is complex, involving impaired glucose levels, insulin resistance, accumulation of advanced glycation end-products, chronic inflammation process, and vascular changes. Preventive strategies, early diagnosis, and adjusted management are crucial to mitigate the impact of these complications on diabetic patients, their mobility, and quality of life. This article aims to highlight the importance of musculoskeletal complications and raise awareness of the significance of integrated management of diabetes. Objective: This review aims to describe several musculoskeletal complications of diabetes mellitus. Materials and Methods: A review of the available literature from the PubMed, Scopus, and Web of Science databases published within the last 20 years.